دورية أكاديمية
أعرض في EDS

IL-1β transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma.

التفاصيل البيبلوغرافية
العنوان: IL-1β transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma.
المؤلفون: Muthupalani S; Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-825C, Cambridge, MA, 02139, USA. smuthupalani@stagebio.com.; StageBio, 5930 Main St, Mount Jackson, VA, 22842, USA. smuthupalani@stagebio.com., Annamalai D; Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-825C, Cambridge, MA, 02139, USA., Feng Y; Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-825C, Cambridge, MA, 02139, USA., Ganesan SM; Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-825C, Cambridge, MA, 02139, USA., Ge Z; Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-825C, Cambridge, MA, 02139, USA., Whary MT; Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-825C, Cambridge, MA, 02139, USA., Nakagawa H; Division of Digestive and Liver Diseases and Herbert Irving Cancer Research Center, Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA., Rustgi AK; Division of Digestive and Liver Diseases and Herbert Irving Cancer Research Center, Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA., Wang TC; Division of Digestive and Liver Diseases and Herbert Irving Cancer Research Center, Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA., Fox JG; Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-825C, Cambridge, MA, 02139, USA. Jgfox@mit.edu.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. Jgfox@mit.edu.
المصدر: Scientific reports [Sci Rep] 2023 Aug 05; Vol. 13 (1), pp. 12732. Date of Electronic Publication: 2023 Aug 05.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Adenocarcinoma*/pathology , Barrett Esophagus*/pathology , Carcinoma, Squamous Cell*/genetics , Carcinoma, Squamous Cell*/complications , Esophageal Neoplasms*/pathology , Esophageal Squamous Cell Carcinoma*/genetics , Head and Neck Neoplasms*/complications , Mouth Neoplasms*/genetics , Mouth Neoplasms*/complications, Animals ; Child, Preschool ; Humans ; Mice ; Inflammation/genetics ; Inflammation/complications ; Metaplasia ; Mice, Transgenic ; Squamous Cell Carcinoma of Head and Neck/complications
مستخلص: Chronic inflammation is integral to the development of esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), although the latter has not been associated with reflux esophagitis. The L2-IL-1β transgenic mice, expressing human interleukin (IL)-1β in the oral, esophageal and forestomach squamous epithelia feature chronic inflammation and a stepwise development of Barrett's esophagus-like metaplasia, dysplasia and adenocarcinoma at the squamo-columnar junction. However, the functional consequences of IL-1β-mediated chronic inflammation in the oral and esophageal squamous epithelia remain elusive. We report for the first time that in addition to the previously described Barrett's esophagus-like metaplasia, the L2-IL-1β mice also develop squamous epithelial dysplasia with progression to squamous cell carcinoma (SCC) in the esophagus and the tongue. L2-IL-1β showed age-dependent progression of squamous dysplasia to SCC with approximately 40% (n = 49) and 23.5% (n = 17) incidence rates for esophageal and tongue invasive SCC respectively, by 12-15 months of age. Interestingly, SCC development and progression in L2-IL-1β was similar in both Germ Free (GF) and Specific Pathogen Free (SPF) conditions. Immunohistochemistry revealed a T cell predominant inflammatory profile with enhanced expression of Ki67, Sox2 and the DNA double-strand break marker, γ-H2AX, in the dysplastic squamous epithelia of L2-IL-1β mice. Pro-inflammatory cytokines, immunomodulatory players, chemoattractants for inflammatory cells (T cells, neutrophils, eosinophils, and macrophages) and oxidative damage marker, iNOS, were significantly increased in the esophageal and tongue tissues of L2-IL-1β mice. Our recent findings have expanded the translational utility of the IL-1β mouse model to aid in further characterization of the key pathways of inflammation driven BE and EAC as well as ESCC and Oral SCC.
(© 2023. Springer Nature Limited.)
References: Antioxid Redox Signal. 2017 Jun 20;26(18):1059-1077. (PMID: 27494631)
Cell Microbiol. 2017 Jul;19(7):. (PMID: 28111881)
Cancer Cell. 2008 Nov 4;14(5):408-19. (PMID: 18977329)
Oncotarget. 2015 Mar 20;6(8):6040-52. (PMID: 25714027)
Mol Cancer. 2013 Apr 05;12:26. (PMID: 23561329)
Hepatogastroenterology. 1999 Mar-Apr;46(26):952-8. (PMID: 10370645)
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1206-11. (PMID: 24695797)
J Cell Biochem. 2018 Aug;119(8):7040-7052. (PMID: 29737564)
Can J Microbiol. 2017 Jun;63(6):475-492. (PMID: 28257583)
Clin Cancer Res. 2016 Jul 1;22(13):3340-7. (PMID: 26847061)
Chin Med J (Engl). 2020 Oct 5;133(19):2386-2388. (PMID: 32804727)
Methods Mol Biol. 2012;921:189-203. (PMID: 23015505)
Trans Am Clin Climatol Assoc. 2019;130:266-271. (PMID: 31516191)
Cancer Commun (Lond). 2019 Nov 26;39(1):79. (PMID: 31771653)
PLoS Genet. 2017 Aug 7;13(8):e1006938. (PMID: 28787442)
Cell Death Discov. 2018 Mar 26;4:46. (PMID: 29844930)
Immunity. 2013 Dec 12;39(6):1003-18. (PMID: 24332029)
Cancer Cell. 2011 Apr 12;19(4):470-83. (PMID: 21481789)
Dis Esophagus. 2014 Apr;27(3):285-93. (PMID: 23902537)
Oncotarget. 2016 Apr 19;7(16):21853-64. (PMID: 26942702)
Nat Commun. 2020 Jul 24;11(1):3715. (PMID: 32709844)
EMBO Mol Med. 2012 Dec;4(12):1276-93. (PMID: 23065753)
Cancer Cell. 2012 Jan 17;21(1):36-51. (PMID: 22264787)
Br J Cancer. 2013 Nov 12;109(10):2629-35. (PMID: 24169351)
J Clin Med. 2019 Oct 21;8(10):. (PMID: 31640140)
Mol Cancer Res. 2020 Dec;18(12):1876-1888. (PMID: 33004621)
J Clin Invest. 2002 Sep;110(6):761-9. (PMID: 12235107)
Int Surg. 2015 Apr;100(4):733-43. (PMID: 25875558)
Cancer Cell Int. 2018 Dec 11;18:203. (PMID: 30559604)
Cancer Epidemiol. 2016 Apr;41:88-95. (PMID: 26851752)
Gastroenterology. 2018 Jan;154(2):360-373. (PMID: 28823862)
Hepatogastroenterology. 2012 Oct;59(119):2186-91. (PMID: 22389297)
Middle East J Dig Dis. 2015 Oct;7(4):257-60. (PMID: 26609356)
Iran Red Crescent Med J. 2011 Jul;13(7):507-9. (PMID: 22737519)
Sci Rep. 2017 Nov 28;7(1):16540. (PMID: 29184122)
Oncotarget. 2016 Mar 29;7(13):15525-38. (PMID: 26771842)
Oncotarget. 2016 Apr 26;7(17):24564-71. (PMID: 27028857)
Cell Stem Cell. 2013 Mar 7;12(3):304-15. (PMID: 23472872)
Gastroenterology. 2010 Dec;139(6):2124-2134.e9. (PMID: 20816834)
Genomics Proteomics Bioinformatics. 2018 Feb;16(1):33-49. (PMID: 29474889)
Int J Clin Oncol. 2010 Apr;15(2):135-44. (PMID: 20224883)
Cancers (Basel). 2020 Jul 04;12(7):. (PMID: 32635472)
Nat Genet. 2009 Nov;41(11):1238-42. (PMID: 19801978)
Oral Surg Oral Med Oral Pathol. 1984 May;57(5):524-31. (PMID: 6427721)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
Int J Mol Sci. 2017 Aug 19;18(8):. (PMID: 28825631)
Ann Transl Med. 2020 Jul;8(13):822. (PMID: 32793667)
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):301-13. (PMID: 14734483)
Adv Cancer Res. 2019;144:95-135. (PMID: 31349905)
Gastroenterology. 2019 Aug;157(2):492-506.e2. (PMID: 30998992)
Curr Opin Immunol. 2016 Apr;39:1-6. (PMID: 26609943)
Esophagus. 2020 Apr;17(2):113-121. (PMID: 31773415)
Mod Pathol. 2017 Jan;30(s1):S112-S118. (PMID: 28060368)
Oncotarget. 2017 Jul 18;8(29):47518-47532. (PMID: 28537901)
Cancer Immunol Immunother. 2020 Jun;69(6):1071-1086. (PMID: 32103293)
Oncotarget. 2016 Nov 15;7(46):76087-76100. (PMID: 27738319)
Mol Cancer. 2020 Jul 17;19(1):116. (PMID: 32680511)
Mol Carcinog. 2019 May;58(5):627-632. (PMID: 30632250)
Life Sci. 2021 Apr 15;271:119156. (PMID: 33548289)
معلومات مُعتمدة: P30 DK132710 United States DK NIDDK NIH HHS; P30 ES002109 United States ES NIEHS NIH HHS; R35 CA210088 United States CA NCI NIH HHS; U54 CA163004 United States CA NCI NIH HHS
المشرفين على المادة: 0 (IL1B protein, mouse)
SCR Disease Name: Adenocarcinoma Of Esophagus
تواريخ الأحداث: Date Created: 20230805 Date Completed: 20230807 Latest Revision: 20240123
رمز التحديث: 20240123
مُعرف محوري في PubMed: PMC10404242
DOI: 10.1038/s41598-023-39907-8
PMID: 37543673
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-023-39907-8